Search Results - "Lezghed, N"

Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance by Guigay, J, Even, C, Mayache-Badis, L, Debbah, M, Saada-Bouzid, E, Tao, Y, Deschamps, F, Janot, F, Lezghed, N, Michel, C

“…Abstract Background Cetuximab, an anti-EGFR monoclonal antibody in combination with platinum and 5FU is the standard of care in first-line treatment of…”
Get full text

Pazopanib in advanced or metastatic synovial sarcoma: The Gustave Roussy experience by Sroussi, M., De Percin, S., Grecea, A.M., Benderra, M.A., Velev, M., Akla, S., Lezghed, N., Dumont, S., Le Péchoux, C., Honore, C., Haddag, L., Faron, M., Terrier, P., Mir, O., Le Cesne, A.

Get full text

OC-014: Molecular screening for cancer treatment optimization in head and neck cancer (MOSCATO 01) by Even, C, Breuskin, I, Ileana, E, Massard, C, Lacroix, L, Lezghed, N, Guigay, J, Janot, F, Soria, J.C, Ferté, C

Get full text

91P Liquid biopsy, a tool to detect genetic alterations with therapeutic impact in international patients: Prospective data on 47 patients from Gustave Roussy by Assi, T.S., Ibrahim, T., Chahine, C., Lezghed, N., Masri, N., Rouleau, E., Caron, O., Le Cesne, A.

Get full text

335MO Intervention combining nurse navigators (NNs) and a mobile application vs standard of care (SOC) in neuro-oncology patients (pts) treated with oral anticancer agents (OAA): A subgroup analysis of CAPRI, a single-center, randomized phase III trial by Duflot-Boukobza, A., Mathivon, D., Legendre, J., Khettab, M., Oinino, S., Ferrua, M., Fourcade, A., Lezghed, N., Dhermain, F., Lemare, F., Guillet, M., Puglisi, V., Abbas, M., Pons, M., Di Palma, M., Minvielle, E., Mir, O., Dumont, S.N.

Get full text

1643PPazopanib in advanced or metastatic synovial sarcoma: The Gustave Roussy experience by Sroussi, M, De Percin, S, Grecea, A M, Benderra, M A, Velev, M, Akla, S, Lezghed, N, Dumont, S, Le Péchoux, C, Honore, C, Haddag, L, Faron, M, Terrier, P, Mir, O, Le Cesne, A

Get full text

High incidence of cetuximab-related infusion reactions in head and neck cancer pts (real life data) by Palomar, V., Annereau, M., Lezghed, N., Even, C., Mayache-Badis, L., Iacob, M., Leibu, C., Matias, M., Bravo, P., Ferte, C.

Get full text

997PRESULTS OF TPEX (DOCETAXEL, CISPLATIN, CETUXIMAB) REGIMEN USE IN FIRST LINE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN A SINGLE INSTITUTION by Even, C., Bobillot, B., Mayache-Badis, L., Ferrand, F.R., Lezghed, N., Bidault, F., Auperin, A., Temam, S., Janot, F., Schilf, A., Guigay, J.

“…Abstract Aim: According to the ESMO guidelines, 5FU, platinum and cetuximab is the standard in first line for patients (pts) with R/M SCCHN (PFEx; Vermorken,…”
Get full text

Results of Tpex (Docetaxel, Cisplatin, Cetuximab) Regimen Use in First Line Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M Scchn) in a Single Institution by Even, C., Bobillot, B., Mayache-Badis, L., Ferrand, F.R., Lezghed, N., Bidault, F., Auperin, A., Temam, S., Janot, F., Schilf, A., Guigay, J.

Get full text